Hainan Free Trade Port held the first batch of national innovative pharmaceutical enterprises Hainan Branch in 2020
China News, Hainan, July 31 (Reporter Wang Ziqian) Hainan Free Trade Port, the first batch of national innovative pharmaceutical enterprises to visit Hainan in 2020, was held in Haikou from July 31 to August 1. The purpose of this activity is to speed up the work process of Hainan Provincial Government's leading project in 2020, "the pilot project for the transfer and transformation of major national scientific and technological special achievements in the development of major new drugs", attract well-known new drug development enterprises at home and abroad to invest in Hainan, improve the innovation level of Hainan's pharmaceutical industry, and help the construction of Hainan Free Trade Port.
During the activity, a round table conference on investment promotion was held. Wang Lu, Vice Governor of Hainan Province, Zheng Fangneng, the second level inspector of the Department of Major Projects of the Ministry of Science and Technology, Chen Xinyu, Deputy Director of the Department of Science and Education of the National Health Commission, Luo Qingming, President of Hainan University and academician of the CAS Member, and other guests, as well as leaders of nearly 100 well-known pharmaceutical enterprises in China, such as Jiangsu Hengrui Pharmaceutical, Shenzhen Mindray Biomedical, Wuming Kangde, Zhengda Tianqing, attended the event.
Innovative pharmaceutical enterprises signed contracts with Hainan Park. Photographed by Wang Ziqian
At the meeting, 5 projects recommended by Haikou National High tech Industrial Development Zone and 2 projects recommended by Boao Lecheng, a total of 7 projects (including 8 new drug varieties introduced and 5 transformation platforms) were signed one by one and landed in Hainan. Among them, Jiangxi Institute of Biological Products Co., Ltd. and Hainan Provincial Drug Administration signed the purchase agreement of Hainan Provincial Drug Institute; Jilin Hezhong Biotechnology Co., Ltd. signed an investment contract with Haikou National High tech Zone on human genetic resource repository and hair follicle stem cell transformation base; The Institute of Biomedicine of Guangdong University of Technology signed a cooperation agreement with Hailing Pharmaceutical to jointly build an anti infection and chronic disease drug research and development center; Aozida Medical Device Service Group and Haihatch Medical Technology Co., Ltd. signed a cooperation agreement on medical device R&D transformation; The Key Laboratory of Pathogenic Microorganisms and Immunology of the Chinese Academy of Sciences and the First Affiliated Hospital of Hainan Medical College signed a cooperation agreement on clinical transformation of Class I new drugs; Shanghai Maoshuo Medical Technology Co., Ltd. signed a cooperation agreement with the Boao Music City Administration to jointly build an advanced medical technology transformation application platform in the Boao Music City pilot area; Shanghai Than Shwe Biomedical Technology Co., Ltd. signed a cooperation agreement with Boao Lecheng Administration Bureau on the implementation of cell drugs in the park.
During the event, the guests went to Haikou National High tech Industrial Development Zone (Mei'an Science and Technology New Town) and Boao Lecheng International Medical Tourism Pilot Zone for field visits.
In March 2020, the Hainan Provincial Government issued the Work Plan for the Pilot Demonstration of the Transfer and Transformation of National Science and Technology Major Special Achievements for the Development of Major New Drugs in Hainan Province, proposing to build "one base" (the pilot demonstration base for the transfer and transformation of achievements relying on Haikou National High tech Zone and Boao Lecheng Pilot Zone) The main tasks of the "four platforms" (building four platforms for the internationalization technology of the pharmaceutical industry, transfer and transformation services for new drug achievements, public technology services for new drug discovery, and drug clinical trial collaboration network), and the "four systems" (improving the four support systems, including system and mechanism, funding diversification support, talent introduction and training, and essential supply guarantee) are to build a major new drug innovation and achievement transformation base with influence and competitiveness in China.